Dendreon Announces Presentation of PROVENGE Data at the American Society of Hematology and the Society of Urologic Oncology Annual Meetings
SEATTLE, Dec. 3, 2010 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) today announced the following PROVENGE® (sipuleucel-T) data presentations taking place at the 52nd American Society of Hematology (ASH) Annual Meeting in Orlando, Florida and the Society of Urologic Oncology (SUO) Annual Meeting in Bethesda, Maryland.
The following data presentations will take place at the ASH Annual Meeting on Saturday, December 4, 2010, at 5:30 p.m. ET:
- A poster titled, "Elevated Eosinophils Following Treatment with Sipuleucel-T in Men with Prostate Cancer is Associated with Antigen-Specific Immune Response and Prolonged Survival (abstract #1491)," presented by Robert Sims, M.D., senior medical director of clinical affairs of Dendreon.
- A poster titled, "Increased Gamma Globulin Following Immunotherapy with Sipuleucel-T is Associated with Antigen-Specific Antibody Responses (abstract #1738)," presented by Dr. Sims.
The following data presentation will take place at the SUO Annual Meeting on Thursday, December 9, 2010, at 4:00 p.m. ET:
- A poster titled, "Sipuleucel-T Immunotherapy for Advanced Prostate Cancer; Integrated Results from Randomized, Double-Blind, Controlled Trials (abstract #22)," presented by Allan Pantuck, M.D., associate professor of urology at the University of California, Los Angeles.
Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development, commercialization and manufacturing of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy (ACI) product candidates designed to stimulate an immune response in a variety of tumor types. Dendreon's first product, PROVENGE® (sipuleucel-T), was approved by the U.S. Food and Drug Administration (FDA) in April 2010. Dendreon is exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. The Company is headquartered in Seattle, Washington and is traded on the NASDAQ Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com/.
This news release contains forward-looking statements that are subject to risks and uncertainties. Factors that could affect these forward-looking statements include, but are not limited to, developments affecting Dendreon's business and prospects, including progress on the commercialization efforts for PROVENGE. Information on the factors and risks that could affect Dendreon's business, financial condition and results of operations are contained in Dendreon's public disclosure filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov . Dendreon cautions investors not to place undue reliance on the forward-looking statements contained in this press release. All forward-looking statements are based on information currently available to Dendreon on the date hereof, and Dendreon undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this press release, except as required by law.
SOURCE Dendreon Corporation
Stueland, Vice President, Corporate Communications and Investor
Relations, +1-206-829-1522, email@example.com, or Susan
Specht, Director, Investor Relations, +1-206-455-2220,
firstname.lastname@example.org, both of Dendreon
Web Site: http://www.dendreon.com
Posted: December 2010